Clinical trials: Overweight, Obesity
Obesity
Harmonic Versus Electro Surgery in Lower Body Lift Procedures
The objective of this study is to determine if the use of The Harmonic™ (an ultrasonic surgical instrument) in Lower Body Lift procedures reduces volume and duration of wound drainage after surgery when compared to Electro…
- Trial name
- LBL (NCT00522171)
- Testing
- The Harmonic™ ultrasonic scalpel
- Where
- 2 sites in United States, Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ethicon Endo-Surgery
Obesity
Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner
The purpose of this study is to determine whether the GI Endobarrier Liner can be reimplanted.
- Trial name
- NCT01372501
- Testing
- Endobarrier Liner
- Where
- Chile
- Volunteers
- 19 people
- Sponsor
- Morphic Medical Inc.
Obesity
StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight
The Roux-en-Y gastric bypass (RNYGB) is a weight loss surgery that involves the creation of a small gastric pouch and rearrangement of the small intestine.
- Trial name
- NCT00939055
- Testing
- StomaphyX
- Where
- 2 sites in United States
- Volunteers
- 112 people
- Sponsor
- EndoGastric Solutions
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Healthy, Obesity, Metabolically
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities.
- Trial name
- NCT05378893
- Testing
- DR10624 for injection
- Where
- New Zealand
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Obesity
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic…
- Trial name
- NCT03486392
- Testing
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3
- Where
- 51 sites in United States, Belgium and 4 more
- Volunteers
- 474 people
- Sponsor
- Janssen Research & Development, LLC
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S
Acquired Hypogonadotropic Hypogonadism, Obesity
A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic…
- Trial name
- NCT02651688
- Testing
- Enclomiphene
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Repros Therapeutics Inc.
Healthy, Obese
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that…
- Conditions
- Healthy, Obese, Overweight
- Trial name
- NCT06186622
- Testing
- Orforglipron, Simvastatin, Digoxin
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Morbid Obesity
European Union (EU) Post-Market Study on Easyband®
The purpose of this study is to collect additional safety, performance and effectiveness data of the Easyband gastric band medical device in the treatment of morbid obesity in 4 European countries where the device is a CE marked…
- Trial name
- NCT00948246
- Testing
- Easyband®
- Where
- 4 sites in Belgium, Italy and 2 more
- Volunteers
- 112 people
- Sponsor
- Allergan Medical
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
- Trial name
- SCALE™ Insulin (NCT02963922)
- Testing
- Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 5 more
- Volunteers
- 396 people
- Sponsor
- Novo Nordisk A/S
Morbid Obesity, Surgery
Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients
The Oxygen Reserve Index (ORi) is a reference that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00.
- Trial name
- NCT03021551
- Testing
- Rainbow sensor
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Masimo Corporation
Non-Alcoholic Steatohepatitis
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
- Trial name
- NCT02287779
- Testing
- SHP626
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Obesity
Evaluation of EndoZip System in Obese Patients Who Failed to Reduce Weight With Non-surgical Weight-loss Methods
A multicenter, prospective, single-arm, open-label, controlled clinical trial aimed to evaluate the safety and effectiveness of the EndoZip system procedure, coupled with lifestyle modifications, for weight reduction in obese…
- Trial name
- NCT04773795
- Testing
- EndoZip System
- Where
- Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Nitinotes Surgical Ltd.
Obesity, Overweight
A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes
The purpose of this study is determine whether the combination of naltrexone SR and bupropion SR is safe and effective in treating obesity in subjects with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT00474630
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Ancillary therapy
- Where
- 53 sites in United States
- Volunteers
- 505 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
Study for Short Term Weight Loss in Candidates for Bariatric Surgery
The purpose of this study is to determine whether the GI Endobarrier Liner is safe and effective.
- Trial name
- NCT00985491
- Testing
- Endobarrier Liner
- Where
- Chile
- Volunteers
- 46 people
- Sponsor
- Morphic Medical Inc.
Pediatric Obesity, Childhood Obesity
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
The primary objective of this study is to describe the pharmacokinetic profiles of VI-0521 in obese adolescents.
- Trial name
- NCT02714062
- Testing
- VI-0521 Mid Dose, VI-0521 Top Dose
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- VIVUS LLC
Obesity
ReShape Intragastric Balloon for the Treatment of Obesity
A prospective, non-randomized, open-label, multi-center study designed to implant up to twenty-six (26) CE-marked ReShape™ Balloons in twenty-six (26) patients with body mass index (BMI) 30-40 to assess the effectiveness of the…
- Trial name
- ITALYIII (NCT01024465)
- Testing
- ReShape Duo Balloon
- Where
- 2 sites in Italy
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- ReShape Lifesciences
Obesity
Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S.
- Trial name
- HOA (NCT06090461)
- Where
- United States
- Volunteers
- 31,889 people
- Sponsor
- Currax Pharmaceuticals